Tech Company Financing Transactions
Selecta Biosciences Funding Round
Selecta Biosciences closed a $38 million Series E funding round on 9/8/2015. Investors included AJU IB Investment, OrbiMed and Osage Partners.
Transaction Overview
Company Name
Announced On
9/8/2015
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series E
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance multiple product candidates from Selecta's Synthetic Vaccine Particle (SVP) platform, which creates antigen-specific immunotherapeutics, with priority implementation of the clinical program for Selecta's lead immunotherapeutic candidate, SEL-212, which is designed to be the first non-immunogenic biologic therapy for gout.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
480 Arsenal St.
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Selecta Biosciences, Inc. (NASDAQ: SELB) is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Werner Cautreels
Chief Financial Officer
John Leaman
Chief Medical Officer
Earl Sands
Chief Operating Officer
Lloyd Johnston
Chief Scientific Officer
Takashi Kishimoto
VP - Bus. Development
Stephen Smolinski
VP - General Counsel
David Abraham
Browse more venture capital transactions:
Prev: 9/7/2015: Uber venture capital transaction
Next: 9/8/2015: Okta venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs